Vol 6, No 6 (2010)
Review paper
Published online: 2011-02-24
Practical tips on the diagnosis and treatment of abnormalities of glucose metabolism in cancer patients
Onkol. Prak. Klin 2010;6(6):343-354.
Abstract
The increasing number of patients suffering from diabetes mellitus, the increasing prevalence and
improving detectability of cancer and the mutual aetiological and pathogenetic interrelations between
diabetes mellitus and cancer necessitate the development of management guidelines for the diagnosis
and treatment of abnormalities of glucose metabolism in this group of patients. Based on experimental
and clinical studies and our own experience we have drawn up simple guidelines for oncologists aimed
to facilitate the management of cancer patients with co-existent abnormalities of glucose metabolism.
Onkol. Prak. Klin. 2010; 6, 6: 343–354
Keywords:
cancerdiabetes mellitusoral hypoglycaemic drugsinsulin
References
- Nicolucci A. Epidemiological aspects of neoplasms in diabetes. Acta Diabetol. 2010; 47(2): 87–95.
- Michels KB, Solomon CG, Hu FB, et al. Nurses' Health Study. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study. Diabetes Care. 2003; 26(6): 1752–1758.
- Ahn J, Schatzkin A, Lacey JV, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med. 2007; 167(19): 2091–2102.
- Friberg E, Orsini N, Mantzoros CS, et al. Diabetes mellitus and risk of endometrial cancer: a meta-analysis. Diabetologia. 2007; 50(7): 1365–1374.
- Lai MS, Hsieh MS, Chiu YH, et al. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006; 43(6): 1295–1302.
- Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst. 2005; 97(22): 1679–1687.
- Stevens RJ, Roddam AW, Beral V. Pancreatic cancer in type 1 and young-onset diabetes: systematic review and meta-analysis. Br J Cancer. 2007; 96(3): 507–509.
- Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008; 300(23): 2754–2764.
- Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med. 2003; 348(17): 1625–1638.
- Heng HHQ, Stevens JB, Bremer SW, et al. The evolutionary mechanism of cancer. J Cell Biochem. 2010; 109(6): 1072–1084.
- Diabetes mellitus and cancer. Eur J Intern Med. 2000; 11(5): 245–252.
- Wysocki PJ, Wierusz-Wysocka B. Obesity, hyperinsulinemia and breast cancer: novel targets and a novel role for metformin. Expert Rev Mol Diagn. 2010; 10(4): 509–519.
- Simon D, Balkau B. Diabetes mellitus, hyperglycaemia and cancer. Diabetes Metab. 2010; 36(3): 182–191.
- Pollak M. Insulin, insulin-like growth factors and neoplasia. Best Pract Res Clin Endocrinol Metab. 2008; 22(4): 625–638.
- Currie CJ, Poole CD, Gale EAM. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia. 2009; 52(9): 1766–1777.
- Gonzalez-Angulo AM, Meric-Bernstam F. Metformin: a therapeutic opportunity in breast cancer. Clin Cancer Res. 2010; 16(6): 1695–1700.
- Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia. 2009; 52(9): 1732–1744.
- Jonasson JM, Ljung R, Talbäck M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia. 2009; 52(9): 1745–1754.
- Colhoun HM. SDRN Epidemiology Group. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia. 2009; 52(9): 1755–1765.
- Barone BB, Yeh HC, Snyder CF, et al. Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008; 300(23): 2754–2764.
- Polskie Towarzystwo ologiczne. Zalecenia kliniczne dotyczące postępowania u chorych na cukrzycę 2010. Diabet Prakt. 2010; 10(supl. A): A1–A50.
- Noy A, Bilezikian JP. Clinical review 63: Diabetes and pancreatic cancer: clues to the early diagnosis of pancreatic malignancy. J Clin Endocrinol Metab. 1994; 79(5): 1223–1231.
- Chari ST, Leibson CL, Rabe KG, et al. Pancreatic cancer-associated diabetes mellitus: prevalence and temporal association with diagnosis of cancer. Gastroenterology. 2008; 134(1): 95–101.
- Lowenfels AB, Maisonneuve P. Risk factors for pancreatic cancer. J Cell Biochem. 2005; 95(4): 649–656.
- Pannala R, Basu A, Petersen GM, et al. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer. Lancet Oncol. 2009; 10(1): 88–95.
- Hamdy O, Carver C. The Why WAIT program: improving clinical outcomes through weight management in type 2 diabetes. Curr Diab Rep. 2008; 8(5): 413–420.
- Kalender A, Selvaraj A, Kim SoY, et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab. 2010; 11(5): 390–401.
- Pongwecharak J, Tengmeesri N, Malanusorn N, et al. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. Pharm World Sci. 2009; 31(4): 481–486.
- Wierusz-Wysocka B, Zozulińska-Ziółkiewicz D. Postępowanie w stanach nagłych i szczególnych u chorych na cukrzycę. Via Medica, Gdańsk 2009: 58–60.
- Bowker SL, Majumdar SR, Veugelers P, et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care. 2006; 29(2): 254–258.
- Bowker SL, Yasui Y, Veugelers P, et al. Glucose-lowering agents and cancer mortality rates in type 2 diabetes: assessing effects of time-varying exposure. Diabetologia. 2010; 53(8): 1631–1637.
- Monami M, Lamanna C, Balzi D, et al. Sulphonylureas and cancer: a case-control study. Acta Diabetol. 2009; 46(4): 279–284.
- Monami M, Lamanna C, Marchionni N, et al. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials. Diabetes Care. 2008; 31(7): 1455–1460.
- Stulc T, Sedo A. Inhibition of multifunctional dipeptidyl peptidase-IV: is there a risk of oncological and immunological adverse effects? Diabetes Res Clin Pract. 2010; 88(2): 125–131.
- Butler PC, Dry S, Elashoff R. GLP-1-based therapy for diabetes: what you do not know can hurt you. Diabetes Care. 2010; 33(2): 453–455.
- Derweesh IH, Diblasio CJ, Kincade MC, et al. Risk of new-onset diabetes mellitus and worsening glycaemic variables for established diabetes in men undergoing androgen-deprivation therapy for prostate cancer. BJU Int. 2007; 100(5): 1060–1065.
- Zozulińska-Ziółkiewicz D, Wierusz-Wysocka B. Algorytmy insulinoterapii w cukrzycy typu 2. W: Grzeszczak W. (red.). Farmakoterapia w cukrzycy. Via Medica, Gdańsk 2010: 190–199.
- Wierusz-Wysocka B, Zozulińska-Ziółkiewicz D. Insulinoterapia w sytuacjach szczególnych u chorych na cukrzycę typu 2. W: Grzeszczak W. (red.). Farmakoterapia w cukrzycy. Via Medica, Gdańsk 2010: 200–218.
- Wierusz-Wysocka B, Zozulińska-Ziółkiewicz D. Postępowanie w stanach nagłych i szczególnych u chorych na cukrzycę. Via Medica, Gdańsk 2009: 93.